ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 January 2023 - 11:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies to
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., Founder, President and Chief Executive Officer, will present
a company overview at the 41st Annual J.P. Morgan Healthcare
Conference on Tuesday, January 10 at 10:30 am PT at the Westin St.
Francis in San Francisco.
A live webcast of the presentation is available
here and can be accessed by visiting the Investors section of ALX
Oncology’s website at www.alxoncology.com and selecting Events
under the News and Events tab. A replay of the webcast will be
archived for up to 30 days following the presentation date.
About ALX Oncology
ALX Oncology is a publicly traded,
clinical-stage immuno-oncology company focused on helping patients
fight cancer by developing therapies that block the CD47 checkpoint
pathway and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain.
Evorpacept has demonstrated promising clinical responses across a
range of hematologic and solid malignancies in combination with a
number of leading anti-cancer agents. ALX Oncology intends to
continue clinical development of evorpacept for the treatment of
multiple solid tumor indications and hematologic malignancies.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212) 600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2023 to Apr 2024